Showing results (11-20 of 27) with videos related to
Sort By:
Pageof 3
The Lancet. Haematology|March 26, 2021
Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14)Sarah Gillessen, Annette Plütschow, Michael Fuchs, et al.Blood Cells, Molecules & Diseases|January 10, 2008
CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphomaOta Fuchs, Dana Provaznikova, Marcela Kocova, et al.Blood Cells, Molecules & Diseases|August 5, 2009
Nature of frequent deletions in CEBPAOta Fuchs, Arnost Kostecka, Dana Provaznikova, et al.Blood|September 16, 2011
Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphomaBoris Böll, Henning Bredenfeld, Helen Görgen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2018
Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study GroupStephanie Sasse, Helen Goergen, Annette Plütschow, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2020
Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study GroupStefanie Kreissl, Horst Müller, Helen Goergen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2012
Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trialBastian von Tresckow, Annette Plütschow, Michael Fuchs, et al.Hemasphere|November 15, 2019
Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma: Updated Results of the Open-Label, International, Randomised Phase 3 HD15 Trial by the German Hodgkin Study GroupAndreas Engert, Helen Goergen, Jana Markova, et al.The Lancet. Oncology|February 26, 2017
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study GroupPeter Borchmann, Heinz Haverkamp, Andreas Lohri, et al.Blood|September 2, 2008
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphomaCarsten Kobe, Markus Dietlein, Jeremy Franklin, et al.Pageof 3